Atria Wealth Solutions Inc. Reduces Stock Holdings in Johnson & Johnson $JNJ

Atria Wealth Solutions Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 48.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,696 shares of the company’s stock after selling 76,662 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Johnson & Johnson were worth $12,386,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. purchased a new stake in Johnson & Johnson during the 1st quarter worth about $218,000. GAMMA Investing LLC increased its position in Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Johnson & Johnson by 6.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 1,698,831 shares of the company’s stock worth $281,734,000 after purchasing an additional 107,009 shares in the last quarter. Finally, Stephens Consulting LLC increased its position in Johnson & Johnson by 13.8% during the 1st quarter. Stephens Consulting LLC now owns 4,714 shares of the company’s stock worth $782,000 after purchasing an additional 571 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JNJ. Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. HSBC lifted their price objective on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $190.96 on Thursday. The firm has a market capitalization of $459.90 billion, a P/E ratio of 18.43, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business’s 50-day simple moving average is $179.68 and its 200-day simple moving average is $164.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is 55.61%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.